Kenneth Fitzpatrick, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,858 of the $3,351 with a category attached, or 85.3%. 29 manufacturers reported payments, led by Astellas Pharma US Inc at 25.3% of the total. Reporting peaked in 2019 at $1,795 and has fallen 97.2% since, to $50 in 2025.
Across 142 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$847
- Johnson & Johnson$263
- Ferring Pharmaceuticals Inc.$257
- Dendreon Pharmaceuticals LLC$234
- AbbVie$195
- Antares Pharma, Inc.$193
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,85885%
- Education$49315%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 28 | $847 |
| Johnson & Johnson | 12 | $263 |
| Ferring Pharmaceuticals Inc. | 9 | $257 |
| Dendreon Pharmaceuticals LLC | 11 | $234 |
| AbbVie | 9 | $195 |
| Antares Pharma, Inc. | 9 | $193 |
| Endo Pharmaceuticals Inc. | 4 | $169 |
| Bayer | 9 | $157 |
| Boston Scientific | 4 | $148 |
| Merck | 6 | $104 |
| Tolmar, Inc. | 4 | $95 |
| Pfizer | 6 | $93 |
| Tolmar Pharmaceuticals, Inc. | 4 | $86 |
| Urovant Sciences Inc | 4 | $76 |
| Teleflex LLC | 2 | $69 |
| Amgen | 3 | $54 |
| Mission Pharmacal Company | 3 | $41 |
| Blue Earth Diagnostics | 2 | $37 |
| Coloplast | 2 | $34 |
| Dentsply IH Inc. | 2 | $31 |
| Olympus America Inc. | 1 | $23 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| Neotract Inc. | 1 | $18 |
| Medtronic | 1 | $17 |
| Metuchen Pharmaceuticals | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,351 in reported general payments places this provider in the 60th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 27 | $451 |
Paid to pharmacies, not to this prescriber.
Other urology in Devon
- John AndersonBethlehem$2.1M
- Demetrius BagleyPhiladelphia$739K
- Paul SieberLancaster$631K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Anthony DimatteoButler$189K
- Angelo BaccalaAllentown$166K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
- Siobhan HartiganPhiladelphia$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.